

ADVANCES IN
Pharmacology and Chemotherapy

VOLUME 15

ADVANCES IN

Pharmacology and Chemotherapy

EDITED BY

Silvio Garattini

*Istituto di Ricerche
Farmacologiche
"Mario Negri"
Milano, Italy*

A. Goldin

*National Cancer Institute
Bethesda, Maryland*

F. Hawking

*Commonwealth Institute
of Helminthology
St. Albans, Herts., England*

I. J. Kopin

*National Institute of
Mental Health
Bethesda, Maryland*

Consulting Editor

R. J. Schnitzer

*Mount Sinai School of Medicine
New York, New York*

VOLUME 15—1978



ACADEMIC PRESS

New York San Francisco London

A Subsidiary of Harcourt Brace Jovanovich, Publishers

COPYRIGHT © 1978, BY ACADEMIC PRESS, INC.

ALL RIGHTS RESERVED.

NO PART OF THIS PUBLICATION MAY BE REPRODUCED OR TRANSMITTED IN ANY FORM OR BY ANY MEANS, ELECTRONIC OR MECHANICAL, INCLUDING PHOTOCOPY, RECORDING, OR ANY INFORMATION STORAGE AND RETRIEVAL SYSTEM, WITHOUT PERMISSION IN WRITING FROM THE PUBLISHER.

ACADEMIC PRESS, INC.

111 Fifth Avenue, New York, New York 10003

United Kingdom Edition published by

ACADEMIC PRESS, INC. (LONDON) LTD.

24/28 Oval Road, London NW1 7DX

LIBRARY OF CONGRESS CATALOG CARD NUMBER: 61-18298

ISBN 0-12-032915-8

PRINTED IN THE UNITED STATES OF AMERICA

ADVANCES IN

Pharmacology and Chemotherapy

VOLUME 15



Y076660

ADVISORY BOARD

D. BOVET

*Istituto Superiore de Sanità
Rome, Italy*

B. B. BRODIE

*National Heart Institute
Bethesda, Maryland*

J. H. BURN

*Oxford University
Oxford, England*

A. CARLSSON

*Department of Pharmacology
University of Göteborg
Göteborg, Sweden*

K. K. CHEN

*Department of Pharmacology
University of Indiana
Indianapolis, Indiana*

J. F. DANIELLI

*Worcester Polytechnic Institute
Worcester, Massachusetts*

R. DOMENJOZ

*Pharmakologisches Institut
Universität Bonn
Bonn, Germany*

B. N. HALPERN

*Département de Médecine
Expérimentale
Collège de France
Paris, France*

A. D. WELCH

*St. Jude Children's Research
Hospital
Memphis, Tennessee*

CONTRIBUTORS TO THIS VOLUME

Numbers in parentheses indicate the pages on which the authors' contributions begin.

J. R. BROWN (161), *Department of Pharmacy, University of Manchester, Manchester, England*

GAETANO DI CHIARA (87), *Institute of Pharmacology, University of Cagliari, Cagliari, Italy*

MICHAEL A. CHIRIGOS (263), *Viral Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland*

GIAN LUIGI GESSA (87), *Institute of Pharmacology, University of Cagliari, Cagliari, Italy*

CONSTANTINE J. GILLESPIE (51), *Library, National Institutes of Health, Bethesda, Maryland*

F. HAWKING (289), *The Commonwealth Institute of Helminthology, St. Albans, England*

D. S. IRELAND* (161), *Department of Pharmacy, University of Manchester, Manchester, England*

STANISLAW M. MIKULSKI (263), *Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland*

FRANCO M. MUGGIA (263), *Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland*

RAM B. RASTOGI† (203), *Department of Pharmacology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada*

MARCEL ROZENCWEIG (1), *Investigational Drug Branch, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, Maryland*

* Present address: Fazakerley Hospital, Liverpool, England.

† Present address: Nordic Research Laboratories, Connlab Holdings Limited, Montreal, Quebec, Canada.

RADHEY L. SINGHAL (203), *Department of Pharmacology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada*

MILAN SLAVIK (1), *Investigational Drug Branch, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, Maryland*

DANIEL D. VON HOFF (1), *Investigational Drug Branch, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, Maryland*

CONTENTS

CONTRIBUTORS TO THIS VOLUME	ix
---------------------------------------	----

Daunomycin: An Anthracycline Antibiotic Effective in Acute Leukemia

DANIEL D. VON HOFF, MARCEL ROZENCWEIG, AND MILAN SLAVIK

I. Introduction	2
II. Chemical and Pharmaceutical Aspects	2
III. Biological Properties	6
IV. Modes of Action	9
V. Experimental Antitumor Activity	13
VI. Animal Toxicity	16
VII. Metabolism and Disposition	20
VIII. Clinical Studies	27
IX. Summary and Conclusions	44
References	45

Drug Information Services

CONSTANTINE J. GILLESPIE

I. Introduction	51
II. Drug Information Retrieval Systems	52
III. Toxicology Information Services	74
IV. Special-Purpose Information Services	79
V. Concluding Remarks	84
References	84

Pharmacology and Neurochemistry of Apomorphine

GAETANO DI CHIARA AND GIAN LUIGI GESSA

I. Introduction	88
II. Chemical Pharmacology of Apomorphine	88
III. Emetic Effects of Apomorphine	95
IV. Behavioral Effects of Apomorphine	99
V. Neuropharmacological Effects of Apomorphine	119

VI. Cardiovascular Effects of Apomorphine	123
VII. Endocrine Effects of Apomorphine	125
VIII. Neurochemical Effects of Apomorphine	127
IX. Clinical Effects of Apomorphine	141
X. Other Dopamine Receptor Agonists	143
References	147
Note Added in Proof	160

Structural Requirements for Tetracycline Activity

J. R. BROWN AND D. S. IRELAND

I. Introduction	161
II. Structure-Activity Relationships	163
III. Structural Features Essential for Activity	174
IV. Effect of Structural Variation on Pharmacokinetic Properties	180
V. Conclusions	192
References	197

Neurotransmitter Mechanisms during Mental Illness Induced by Alterations in Thyroid Function

RADHEY L. SINGHAL AND RAM B. RASTOGI

I. Introduction	204
II. Evidence for Neuroendocrine Abnormalities in Mental Dysfunction	205
III. Hyperthyroidism and Related Mental Illness	210
IV. Lithium: Influence on Behavior and Brain Monoamines in Neonatally Hyperthyroid Rats	220
V. Diazepam: Influence on Locomotor Performance and Brain Biogenic Amines in Hyperthyroid Rats	228
VI. Depression vs Hypothyroidism	234
VII. Neurochemical Correlates of Suppressed Behavior during Hypothyroidism	235
VIII. Thyroid Hormones and Critical Period of Brain Development	242
IX. Combined Use of Tricyclic Antidepressants and Thyroid Hormone: Possible Neurochemical Basis	243
X. Summary and Concluding Remarks	251
References	255

Immune Modulation and Cancer Control

STANISLAW M. MIKULSKI, MICHAEL A. CHIRIGOS, AND FRANCO M. MUGGIA

I. Introduction	263
II. Components of the Immune System	264
III. Interfering Factors	272

IV. Immunological Testing	275
V. Suggestions for Improvement of Immunotherapy Trials	276
VI. Summary	281
References	282

Suramin: With Special Reference to Onchocerciasis

F. HAWKING

I. Introduction	289
II. Chemistry	290
III. Absorption and Distribution	291
IV. Biochemistry and Pharmacology	293
V. Toxicity	298
VI. Antiparasitic Action	304
VII. Therapeutic Use	313
References	319
SUBJECT INDEX	323

Daunomycin: An Anthracycline Antibiotic Effective in Acute Leukemia

DANIEL D. VON HOFF, MARCEL ROZENCWEIG, AND MILAN SLAVIK

*Investigational Drug Branch, Division of Cancer Treatment
National Cancer Institute
National Institutes of Health, Bethesda, Maryland*

I.	Introduction	2
II.	Chemical and Pharmaceutical Aspects	2
A.	Description	2
B.	Chemical Properties and Structure-Activity Relationship	3
C.	Other Drugs Equivalent to Daunomycin	4
D.	Pharmaceutical Data	5
III.	Biological Properties	6
A.	Antibacterial Activity	6
B.	Antibacteriophage Activity	6
C.	Antiviral Activity	6
D.	Cytotoxic and Antineoplastic Activity	6
E.	Teratogenic Effect	7
F.	Immunosuppressive Effect	7
G.	Inhibition of X-Ray Repair	8
H.	Anticoagulant Effect	8
I.	Enhancement of Rat Liver Uridine Kinase	8
IV.	Modes of Action	9
A.	Mechanisms	9
B.	Phase Specificity	12
C.	Resistance to Daunomycin	13
V.	Experimental Antitumor Activity	13
A.	Cytosine Arabinoside (Ara-C) + Daunomycin	15
B.	VP16-213 (NSC 141540) + Daunomycin	15
C.	L-Asparaginase + Daunomycin	16
D.	Daunomycin + Ara-C + 6-Mercaptopurine	16
VI.	Animal Toxicity	16
A.	Quantitative Toxicity	16
B.	Qualitative Toxicity	18
C.	Toxic Effects in the Rabbit	19
D.	Perfusion Studies	20
VII.	Metabolism and Disposition	20
A.	<i>In Vitro</i> Studies	20
B.	Metabolism in Rodents	22
C.	Metabolism in the Rabbit	23
D.	Metabolism in the Dog	24
E.	Metabolism and Pharmacokinetics in Man	25

VIII.	Clinical Studies	27
A.	Phase I Studies	28
B.	Phase II and III Studies	29
C.	Toxicity in Man	39
IX.	Summary and Conclusions	44
	References	45

I. Introduction

The Division of Cancer Treatment (DCT) of the National Cancer Institute (NCI) in its drug development function sponsors clinical trials with investigational anticancer drugs. These drugs are gathered from various sources, with about two-thirds coming from the DCT drug-screening program and about one-third from a cooperative drug exchange program conducted throughout the world. Among the interesting anticancer drugs developed abroad is daunomycin, an antitumor antibiotic of the anthracycline group. The drug was isolated in 1963, and in the last 13 years a large amount of preclinical and clinical data has accumulated. This information requires an updated analysis, particularly in light of the fact the drug has shown a substantial amount of activity in acute leukemia refractory to other antileukemic drugs.

II. Chemical and Pharmaceutical Aspects

A. DESCRIPTION

In 1961, Arcamone and his colleagues studied substances isolated from *Streptomyces* cultures that had been obtained from a soil sample from India. These substances had a marked influence on Ehrlich ascites tumors and Sarcoma 180 tumors in mice (Arcamone *et al.*, 1961).

Daunomycin is an antitumor antibiotic of the anthracycline group, which was isolated in the Farmitalia Research Laboratories in Milan, Italy, from cultures of *Streptomyces peucetius* by Grein *et al.* in 1963. The major part of the drug was found in the culture media of the mycelium and was isolated by means of solvent extraction, cation resins, and paper or column chromatography. The yield was 5–15 mg of product per liter of culture media. The soil sample was from Castel del Monte, near Puglie, and hence the name of the species *S. peucetius*.

The drug is classified as an anthracycline and has similar physico-chemical characteristics to rhodomycins, cynerubines, pyrromicins, and rutilantines (DiMarco *et al.*, 1964b; Cassinelli and Orezzi, 1963). Other

names for the drug include daunorubicin HCl, rubidomycin, rubomycin C, Cerubidine, and NSC 82151.

Daunomycin consists of a pigmented aglycone (daunomycinone) in glycoside linkage with an amino sugar (daunosamine) (DiMarco *et al.*, 1964b); the structure is depicted in Fig. 1. Total synthesis of daunomycin was reported by Acton *et al.* in 1974.

B. CHEMICAL PROPERTIES AND STRUCTURE-ACTIVITY RELATIONSHIP

Chemical properties necessary for identifying daunomycin are listed in Table I.

The structure-activity relationship of daunomycin has been commented on by Zee-Cheng and Cheng (1970). They found a common structural feature was shared by some nonalkylating antileukemic agents such as aminopterin, anthramycin, 5-azacytidine, camptothecin, cytosine arabinoside, emetine, demecolcine, riboside, methotrexate, streptognirin, vinblastine, vincristine, and daunomycin. This structural feature is a triangulation between 1 nitrogen and 2 oxygen atoms with rather definite interatomic distances. For daunomycin, the N—O—O triangulation pattern is shown in Fig. 2 with the following interatomic distances:

$$\text{N—O}_1 = 7.05\text{--}10.20 \text{ \AA}$$

$$\text{N—O}_2 = 8.36\text{--}11.40 \text{ \AA}$$

$$\text{O}_1\text{—O}_2 = 2.70 \text{ \AA}$$

The relationship of this triangulation pattern and antileukemic activity is substantiated by reports that neither the aglycone of daunomycin alone




FIG. 1. The structure of daunomycin.

TABLE I

CHEMICAL PROPERTIES OF DAUNOMYCIN

Description
Red powder or thin red needles
Melting point, 188°–190°C
Molecular weight = 563.99 (anhydrous)
The pK_a equals 10.3. The color in aqueous solution varies according to pH of solution: pink at acid pH and blue at alkaline pH.
Elemental composition
Carbon, 57.5
Hydrogen, 5.36
Chlorine, 6.29
Oxygen, 28.4
Specific rotation
$[\alpha]_D = 253^\circ$ (reproducibility difficult due to intense color of solution)
Solubility
In water = 450 mg/ml
Also soluble in methanol
Insoluble in chloroform, ether, and benzene
Thin-layer chromatography
Absorbent— SiO_2
Solvent system— <i>sec</i> -butanol/pyridine/water (1/1/1)
Detection—visible, UV

(daunomycinone) nor the amino sugar (daunosamine) possesses antileukemic activity.

Other portions of the molecule of daunomycin have been thought to be important for antitumor activity. Daunomycin, adriamycin, rubidazone, and daunomycinone were tested for their ability to inhibit oncornavirus DNA polymerase. All compounds were found to be potent inhibitors of DNA polymerase purified from avian myeloblastosis virus and Rauscher murine leukemia virus. Inhibition was found to be due to the tetracyclic planar ring structure (daunomycine) common to all of these compounds (Schafer and Papas, 1975).

Calendi *et al.* (1965) have found that the amino group of the sugar is necessary for tight binding to the DNA molecule.

C. OTHER DRUGS EQUIVALENT TO DAUNOMYCIN

Dubost *et al.* (1964) isolated a product having physicochemical and analytical characteristics identical to daunomycin from a culture broth of *Streptomyces coeruleorubidus* and called it rubidomycin. The compounds were determined to be identical by the following studies: elemental analysis; melting point; thin-layer chromatography; ultraviolet

spectrum; infrared spectrum; nuclear magnetic resonance; benzoate derivatives of both drugs; and X-ray diffraction patterns.

Rubomycin was produced from *S. coeruleorubidus* and was isolated in the Soviet Union. The drug represents a complex of two chemically related variants, namely, rubomycin B and rubomycin C. Rubomycin C is identical to daunomycin but rubomycin B is different from daunomycin (Gause, 1966).

D. PHARMACEUTICAL DATA

Daunomycin is commercially available in Europe but in the United States is available only as an investigational agent through the Investigational Drug Branch of the National Cancer Institute. The product is supplied as a lyophilized cake in vials containing 21.4 mg of daunomycin hydrochloride equivalent to 20 mg of daunomycin base. In addition, the vials also contain 100 mg of mannitol. The intact vials should be stored at room temperature (22°C) protected from light. When reconstituted with 4 ml of sodium chloride for injection, USP, each milliliter of solution contains 5 mg of daunomycin base.

Intact vials are stable for at least 3 years at room temperature (22°C). The reconstituted drug should be used within 8 hours or discarded since the lyophilized cake contains no preservatives.




FIG. 2. Triangulation pattern of daunomycin. (From Zee-Cheng and Cheng, 1970, American Pharmaceutical Association. Adapted by permission of the copyright owner.)

III. Biological Properties

Daunomycin possesses an impressive number of biological effects.

A. ANTIBACTERIAL ACTIVITY

Sanfilippo and Mazzoleni (1964) found that *Escherichia coli* Type B was sensitive to daunomycin but *E. coli* K12 was much less sensitive. They ascribed the differences in sensitivities to possible differences in cellular penetration of the daunomycin. Parisi and Soller (1964) found that daunomycin had no effect on growth of *E. coli* B or *E. coli* K12 in concentrations up to 80 $\mu\text{g/ml}$. When concentrations of up to 300 $\mu\text{g/ml}$ of daunomycin were used, there was a lengthening of the division time to one-half more than normal. The drug has been found to be bacteriostatic against gram-positive organisms especially *Staphylococcus aureus* (Sanfilippo and Mazzoleni, 1964).

Pruzanski and Saito (1974) noted that daunomycin mixed with normal human or leukemic serum did not influence *in vitro* or *in vivo* levels of serum immunoglobulins, lysozyme, or total hemolytic complement. At low doses of daunomycin, there was slight inhibition of bacteriolytic activity of normal sera against *E. coli*. With high doses of daunomycin, there was enhancement of the bacteriolytic activity of normal serum.

B. ANTIBACTERIOPHAGE ACTIVITY

Daunomycin inhibits the multiplication of bacteriophage (Cassinelli and Orezzi, 1963). It strongly inhibits DNA phages by acting during the replication cycle of the phage and not on absorption, injection, or lysis. The RNA phage growth was unaffected by daunomycin. The antiphage activity was proportional to the concentration of daunomycin. The antiphage activity was partially blocked by DNA but not by nucleotides or nucleosides (Parisi and Soller, 1964; Sanfilippo and Mazzolini, 1964).

C. ANTIVIRAL ACTIVITY

Daunomycin does not inhibit multiplication of vaccinia, herpes, adenoviruses, or influenza virus (Dubost *et al.*, 1964).

D. CYTOTOXIC AND ANTINEOPLASTIC ACTIVITY

Cytotoxicity and antitumor activity are dealt with in depth in the following sections. Di Marco *et al.* (1964a) reported that daunomycin had marked inhibitory activity on Ehrlich ascites and Sarcoma 180 ascites tumors in mice and also on hepatoma AH130 and Walker

carcinoma (see Section V). Rat fibroblast and HeLa and KB cell monolayers in cell cultures treated with daunomycin had marked alterations in the nucleus, nucleoli, and chromosomes with dramatic growth inhibition at 1 $\mu\text{g/ml}$. The antibiotic also stopped the mitotic activity in cells that have completed the DNA replication cycle and were in G_2 phase (Di Marco *et al.*, 1967).

E. TERATOGENIC EFFECT

Daunomycin has been teratogenic in chick embryos treated on the fourth day of incubation but has not been teratogenic in mice or rabbits. The type of malformations in the chick were largely joint deformities, syndactyly, and torsions (Dubost *et al.*, 1964).

F. IMMUNOSUPPRESSIVE EFFECT

Gericke and Chandra (1973) found that at low doses, daunomycin stimulates immune responses, with increases in plaque-forming cells in mouse spleen in animals sensitized with sheep red blood cells (SRBC) as well as increases in hemagglutinins to SRBC. At higher doses, there is distinct immunosuppression with the opposite effects in these two systems.

Umezawa *et al.* (1972) noted that timing of SRBC antigen administration was an important factor. If antigen was given 24 hours after daunomycin administration, the number of plaque-forming cells and the hemagglutination titers to SRBC increased, meaning increased immune response. If the antigen was given 24 hours before daunomycin administration, the number of plaque-forming cells decreased, indicating immunosuppression but the hemagglutination titers to SRBC remained the same.

The possibility has been considered that adriamycin is less immunosuppressive than daunomycin and that this difference is in part responsible for the greater therapeutic effects of adriamycin in certain transplantable tumor systems. The immunosuppressive effects of adriamycin and daunomycin were compared using complement-dependent and independent cellular toxicity as an *in vitro* assay of immunity. No significant differences in the effects of adriamycin and daunomycin were seen in that test system (Orsini and Mihich, 1975).

Schwartz (1974) stated that in P388 leukemia in mice, adriamycin has a greater antitumor activity than daunomycin. This therapeutic advantage is lost when the host is pretreated with whole-body radiotherapy. This result suggests that daunomycin is more immunosuppressive than adriamycin.